[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-349044-105":59,"doc-detail-349044-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","tumour-targeted-fluorescence-guided-surgery-in-gastrointestinal-cancer-a-systematic-review-of-preclinical-and-clinical-research","Tumour-targeted fluorescence-guided surgery in gastrointestinal cancer - A systematic review of preclinical and clinical research","","Gastrointestinal cancers cause substantial cancer-related morbidity and mortality, and surgery remains central to curative care. Tumour-targeted fluorescence-guided surgery (tFGS) aims to improve intraoperative visualisation and oncological precision. A systematic review registered in PROSPERO (ID: 558994) and following PRISMA evaluated 133 eligible preclinical and clinical studies, identifying nine clinically tested tracers and multiple preclinical targets. Clinical data show tumour-to-background ratios up to 6.1 ex vivo and surgical strategy changes in up to 35% of cases, while translation is constrained by heterogeneity, biomarker variability, regulatory hurdles, and limited phase III evidence.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/tumour-targeted-fluorescence-guided-surgery-in-gastrointestinal-cancer-a-systematic-review-of-preclinical-and-clinical-research/349044/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/tumour-targeted-fluorescence-guided-surgery-in-gastrointestinal-cancer-a-systematic-review-of-preclinical-and-clinical-research/349044.png","ImageObject",300,407,{"name":92,"@type":93},"Sarah ","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-24","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main focus of this systematic review?","Question",{"text":112,"@type":113},"The review evaluates preclinical and clinical research on tumour-targeted fluorescence-guided surgery (tFGS) for gastrointestinal cancer, including evaluated tracers and their reported performance in surgery.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was the review conducted and what evidence base was included?",{"text":117,"@type":113},"Studies were registered in PROSPERO (ID: 558994) and followed PRISMA guidelines, searching PubMed and Embase to identify 133 eligible preclinical and clinical studies.",{"name":119,"@type":110,"acceptedAnswer":120},"What outcomes and limitations are reported regarding clinical translation?",{"text":121,"@type":113},"Clinical trials reported tumour-to-background ratios up to 6.1 ex vivo and strategy changes in up to 35% of cases, but routine practice translation is limited by heterogeneity, regulatory hurdles, biomarker variability, and the absence of phase III trials.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},349044,1790896467,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},962085320529,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","DOI: 10.1002/ctm2.70615  \nREVIEW  \nTumour-targeted fluorescence-guided surgery in gastrointestinal cancer: A systematic review of preclinical and clinical research  \nAaya Darai1   Evie H. M. Graus1   Femke J. A. van der Stroom1 Mark Rijpkema2  Alexander Vahrmeijer3  Denise E. Hilling3, 4  Johannes H. W. De Wilt1  Merlijn Hutteman1  \n1 Department of Surgery, Radboud University Medical Centre, Nijmegen, The Netherlands  \n2 Department of Medical imaging, Nuclear medicine, Radboud University Medical Centre, Nijmegen, The Netherlands  \n3 Department of Surgery, Leiden University Medical Centre, Leiden, The Netherlands  \n4 Department of Surgical Oncology and Gastrointestinal Surgery, Erasmus MC Cancer Institute, University Medical Centre Rotterdam, Rotterdam, The Netherlands  \nCorrespondence  \nAaya Darai and MerlijnHutteman, Department of Surgery–Route 618, Radboud University Medical Center, Geert Grooteplein Zuid 10, 6525GA Nijmegen, The Netherlands.  \nEmail: Aaya.darai@radboudumc.nland [merlijn.hutteman@radboudumc.nl](merlijn.hutteman@radboudumc.nl)  \n[Aaya DaraiandEvieH. M. Graus share the](Aaya DaraiandEvieH. M. Graus share the)[ ](Aaya DaraiandEvieH. M. Graus share the)[first authorship.](first authorship.)  \nGraphical Abstract  \n∙ Tumour-targeted fluorescence-guided surgery (Ttfgs) enhances intraoperative precision in gastrointestinal cancer treatment.  \n∙ Translation of (Ttfgs) into clinical practice is limited by heterogeneity, regulatory hurdles, biomarker variability and absence of phase III trials.  \n∙ Innovations such as multimodal tracers and theranostic agents may further enhance the precision and therapeutic potential ofTtfgs.  \nDOI: 10.1002/ctm2.70615  \nREVIEW  \nTumour-targeted fluorescence-guided surgery in gastrointestinal cancer: A systematic review of preclinical and clinical research  \nAaya Darai1   Evie H. M. Graus1   Femke J. A. van der Stroom1 Mark Rijpkema2  Alexander Vahrmeijer3  Denise E. Hilling3, 4  Johannes H. W. De Wilt1  Merlijn Hutteman1  \n1 Department of Surgery, Radboud University Medical Centre, Nijmegen, The Netherlands  \n2 Department of Medical imaging, Nuclear medicine, Radboud University Medical Centre, Nijmegen, The Netherlands  \n3 Department of Surgery, Leiden University Medical Centre, Leiden, The Netherlands  \n4 Department of Surgical Oncology and Gastrointestinal Surgery, Erasmus MC Cancer Institute, University Medical Centre Rotterdam, Rotterdam, The Netherlands  \nCorrespondence  \nAaya Darai and Merlijn Hutteman, Department of Surgery – Route 618, Radboud University Medical Center, Geert Grooteplein Zuid 10, 6525GA Nijmegen, The Netherlands.  \nEmail: [Aaya.darai@radboudumc.nl](Aaya.darai@radboudumc.nl) and [merlijn.hutteman@radboudumc.nl](merlijn.hutteman@radboudumc.nl)  \n[Aaya Darai and Evie H. M. Graus share](Aaya Darai and Evie H. M. Graus share)[ ](Aaya Darai and Evie H. M. Graus share)[the first authorship.](the first authorship.)  \nAbstract  \nBackground: Gastrointestinal cancers remain a leading cause of cancer-related morbidity and mortality worldwide, with surgery being central to curative treatment. Tumour-targeted fluorescence-guided surgery (tFGS) has emerged as a promising approach to improve intraoperative visualisation and oncological precision.  \nMethods: We conducted a systematic review of preclinical and clinical studies on tFGS in gastrointestinal oncology, registered in PROSPERO (ID: 558994) and following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Searches of PubMed and Embase identified 133 eligible studies. Results: Nine tracers have currently been evaluated in clinical trials, targeting the following biomarkers: carcinoembryonic antigen, vascular endothelial growth factor, epidermal growth factor receptor, folate receptor α and/or β, integrin αvβ3, 5-aminolevulinic acid and acidic tumour microenvironment. Clinical trials demonstrated that tracers like SGM-101 and panitumumab– IRDye800CW can achieve high tumour-to-background ratios ","cbCaib2ZmfVPFFFC","https://ap.wps.com/l/cbCaib2ZmfVPFFFC","pdf",1762367,22,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusion\n# Graphical Abstract\n## Key points","[{\"question\":\"What is the main focus of this systematic review?\",\"answer\":\"The review evaluates preclinical and clinical research on tumour-targeted fluorescence-guided surgery (tFGS) for gastrointestinal cancer, including evaluated tracers and their reported performance in surgery.\"},{\"question\":\"How was the review conducted and what evidence base was included?\",\"answer\":\"Studies were registered in PROSPERO (ID: 558994) and followed PRISMA guidelines, searching PubMed and Embase to identify 133 eligible preclinical and clinical studies.\"},{\"question\":\"What outcomes and limitations are reported regarding clinical translation?\",\"answer\":\"Clinical trials reported tumour-to-background ratios up to 6.1 ex vivo and strategy changes in up to 35% of cases, but routine practice translation is limited by heterogeneity, regulatory hurdles, biomarker variability, and the absence of phase III trials.\"}]","Tumour-targeted fluorescence-guided surgery in gastrointestinal cancer - A systematic review of preclinical and clinical research | PDF",1790081362,55,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/70f04943eabab7ecea4f93075df7d58c.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/385e521aceaf891e862ca4f5321a375d.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7ad35562ca9a9a59c999ca1dbcec5bfd.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c0426efb1761e764f28be020114faff7.webp",980,1287]